高碳酸血症治疗对脊髓损伤后呼吸恢复的影响 (RECOV2SCI)
It is estimated that 1,275,000 people in the United States alone live with spinal cord injury, including around 100,000 Veterans with spinal cord injury, making the V.A. the largest integrated health care system in the world for spinal cord injuries injury care. New therapies are needed to prevent the morbidities and mortalities associated with the high prevalence of respiratory disorders in Veterans with spinal cord injury. The current research project and future studies would set the base for developing innovative therapies for this disorder. This proposal addresses a new therapeutic intervention for sleep apnea in spinal cord injury. The investigators hypothesized that daily hypercapnia treatments improve respiratory symptoms and alleviate sleep apnea in patients with chronic spinal cord injury. The investigators will perform a pilot study to examine the impact of daily hypercapnia treatments for-two week durations among Veterans with spinal cord injury. The investigators believe that this novel approach to treating sleep apnea and will yield significant new knowledge that improves the health and quality of life of these patients.
研究概览
详细说明
One of the most devastating consequences of cervical spinal cord injury (SCI) is damage to the phrenic motor network, controlling the diaphragm (primary muscle of breathing). Subsequent diaphragm paralysis or paresis results in life-threatening impairments in breathing and can necessitate a need for ventilator assistance. Respiratory and cardiovascular complications are the most common causes of death in the first year post-injury (51% combined). Thus, there is an urgent need to develop strategies for improving function for people with acute and chronic spinal cord injury. Currently, treatments for respiratory dysfunction in spinal cord injury patients are limited to mechanical devices or nerve pacing. Moreover, the proposed plan of studying respiratory muscle training in spinal cord injury patients is novel. However, it is based on animal and human studies that have shown with validity that respiratory muscle training using mild intermittent hypoxia improves respiratory function following SCI. However, the effect of intermittent hypoxia has shown to be dependent on the level of alveolar CO2 and may pose undesirable cardiovascular effects. Previous studies showed that respiratory recovery following SCI manifests by a delayed and partial restorative spontaneous plasticity. The current research project and future anticipated studies would set the base for developing innovative therapies that can stimulate respiratory plasticity hence recovery for this prevalent disorder.
The proposed pilot/feasibility study will test the effect of daily acute intermittent hypercapnia (dAIHc) in individuals with SCI. The objectives of this study are to (1) determine recruitment rates and test the feasibility of recruitment, (2) calculate withdrawal and dropout rates, (3) test the feasibility and tolerability and acceptability of the proposed intervention in an SCI population, (4) develop and refine a new respiratory training intervention using dAIHc paradigm (5) derive effect size estimates for clinical endpoints and their associated variability at the end of treatment to calculate an appropriate sample size for an adequately powered clinical trial. Compared to sham therapy, the central hypothesis is that the daily respiratory muscle training (dAIHc) approach is acceptable and feasible in patients with SCI and will strengthen respiratory muscles and reduce the severity of sleep-disordered breathing (SDB), and will improve daytime symptoms.
This study is highly innovative and the first of its kind in patients with SCI, as it seeks first to use a new set of rehabilitative exercises to improve ventilation and respiratory muscles strength; secondly, it aims to use controlled randomized design; finally, it will determine the role of respiratory muscle exercises in reducing the severity of sleep symptoms and daytime function in SCI. Each aim is independently testable and does not depend on the result of the other aims. The findings will likely apply to a broad range of other neuromuscular diseases (such as Multiple Sclerosis and Stroke). The team of this pilot project has the resources and IRB approval necessary to execute the project.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Abdulghani Sankari, MD PhD
- 电话号码:63499 (313) 576-1000
- 邮箱:Abdulghani.Sankari@va.gov
学习地点
-
-
Michigan
-
Detroit、Michigan、美国、48201-1916
- 招聘中
- John D. Dingell VA Medical Center, Detroit, MI
-
接触:
- Abdulghani Sankari, MD PhD
- 电话号码:63499 313-576-1000
- 邮箱:Abdulghani.Sankari@va.gov
-
首席研究员:
- Abdulghani Sankari, MD PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adult patients with chronic SCI/D (>6 months post-injury)
- American Spinal Injury Association (ASIA) classification A-D who have evidence of SDB (excluding those with no evidence of a neurologic deficit based on ASIA classification)
- Able-bodied patients (without SCI/D0 who have OSA.
Exclusion Criteria:
- Receiving continuous mechanical ventilation (except PAP therapy which is considered usual treatment for SDB
- Severe congestive heart failure with ejection fraction <35%
- Recent health event that may affect sleep
- stroke
- acute myocardial infarction
- recent surgery
- hospitalization
- Alcohol or substance abuse (<90 days sobriety)
- Self-described as too ill to engage in study procedures
- Evidence of hypercapnia on spontaneous breathing (end-tidal CO2 >50 mmHg)
- Unable to provide self-consent for participation
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Intervention hypercapnia arm
Intermittent hypercapnia treatment five days per week for two weeks. |
Intermittent hypercapnia treatment five days per week for two weeks. |
|
实验性的:SCD
Intermittent hypercapnia treatment five days per week for two weeks. |
Intermittent hypercapnia treatment five days per week for two weeks. |
|
实验性的:Able-Bodoed
Intermittent hypercapnia treatment five days per week for two weeks. |
Intermittent hypercapnia treatment five days per week for two weeks. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recruitment rate
大体时间:2 weeks
|
Determine the recruitment rate in the intervention arm and determine how many continue into the sham arm. (Number of patients enrolled and completed the study) |
2 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Minute Ventilation
大体时间:2 weeks
|
To measure the change in minute ventilation (L/min) |
2 weeks
|
|
Change in sleep apnea severity
大体时间:2 weeks
|
Severity of sleep apnea (Apnea-hypopnea index -events/hour) |
2 weeks
|
合作者和调查者
调查人员
- 首席研究员:Abdulghani Sankari, MD PhD、John D. Dingell VA Medical Center, Detroit, MI
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- B4114-P
- 1I21RX004114-01A1 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Publications from research will be made available to the public through the national Library of Medicine PubMed within one year after the date of publication. Final data sets underlying all publications resulting form the proposed research will be shared outside if the following criteria is met: A limited Dataset will be created and shared pursuant to Data Use Agreement (DUA) appropriately limiting use for dataset and prohibiting the recipient from identifying or re-identifying any individuals whose data are included in the dataset.
IPD 共享时间框架
Within one year of the publication
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.